Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose Carboplatin, Paclitaxel, and Topotecan With PBSC Support in Stage III Ovarian and Primary Peritoneal Carcinoma
NCT00004221Phase 2Terminated
- Sponsor
- GOG Foundation
- Start
- Nov 1999
- Primary completion
- Feb 2002
- Modality
- DNA Intercalators/Alkylators, Targeted Liposomes, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, Paclitaxel Micelles for Injection and topotecan liposome in ovarian cancer and primary peritoneal carcinoma (PPC), sponsored by GOG Foundation. Primary endpoints: Complete Response up to 11 years and Indication of Excessive Toxicity up to 11 years. Started Nov 1999; status: terminated.
02
Drugs
carboplatinPaclitaxel Micelles for Injectiontopotecan liposome
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00004221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004221.